This clinical trial studies various targeted anti-cancer treatments in patients with advanced cancer. The study uses genetic testing of tumors to match patients with specific medications that may work best for their type of cancer. The medications being tested include vemurafenib, axitinib, trastuzumab emtansine, selpercatinib, olaparib, pertuzumab, alectinib, atezolizumab, avelumab, vismodegib, pemigatinib, trastuzumab, and niraparib.
The medications are given either as tablets taken by mouth or as infusions given through a vein. The purpose is to evaluate how well these targeted treatments work against cancers that have specific genetic changes. The study will look at whether tumors shrink or stop growing after 16 weeks of treatment.
During the study, patients will receive one of the targeted treatments based on their tumor’s genetic profile. Doctors will monitor how the cancer responds to treatment and watch for any side effects. Patients will have regular check-ups including physical exams and imaging scans to measure their tumors. Blood samples and additional tumor samples may be collected to study how the cancer responds to treatment.
Denmark 
